(Q36614710)

15 August 2017

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype (English)

1 reference

15 August 2017

1 reference

1 reference

1 reference

R Eeles

13

0 references

Douglas F. Easton

11

object named as

D Easton

1 reference

15 August 2017

9

Z Kote-Jarai

1 reference

15 August 2017

A Mitra

1

1 reference

15 August 2017

C Fisher

2

1 reference

15 August 2017

C S Foster

3

1 reference

15 August 2017

C Jameson

4

1 reference

15 August 2017

Y Barbachanno

5

1 reference

15 August 2017

J Bartlett

6

1 reference

15 August 2017

E Bancroft

7

1 reference

15 August 2017

R Doherty

8

1 reference

15 August 2017

S Peock

10

1 reference

15 August 2017

IMPACT and EMBRACE Collaborators

12

1 reference

15 August 2017

language of work or name

English

0 references

publication date

8 January 2008

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

98

1 reference

15 August 2017

2

1 reference

15 August 2017

502-507

1 reference

Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading.

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

Pitfalls in the diagnosis of prostatic cancer: retrospective review of 1791 cases with clinical outcome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

Cancer Incidence in BRCA1 mutation carriers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

Cancer risks in BRCA2 mutation carriers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. CRC/BPG UK Familial Prostate Cancer Study Collaborators.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

BRCA2 mutation in Icelandic prostate cancer patients

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

Intraobserver and interobserver reproducibility of WHO and Gleason histologic grading systems in prostatic adenocarcinomas.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361443

Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604132

Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604132

Classification of prostatic carcinomas

21 January 2018

1 reference

12 December 2020

Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies

1 reference

12 December 2020

Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic

1 reference

12 December 2020

Gleason score, age and screening: Modeling dedifferentiation in prostate cancer

1 reference

12 December 2020

BRCA2 mutation in a family with hereditary prostate cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6604132

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

18182994

1 reference